Navigation Links
Swiss study suggests surgery may offer best chance of long-term prostate cancer survival
Date:10/8/2007

A study from Switzerland suggests that men who have surgery for prostate cancer appear less likely to die of the disease within 10 years than men who choose other treatment options, especially if they are younger or have cancers with certain tumor cell characteristics, according to a report in the Oct. 8 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

Prostate cancer treatments are still being debated because they have not yet been compared in a randomized trial, in which men would be randomly assigned to one treatment or another, according to background information in the article. Therefore, treatment choice is strongly influenced by patient and physician personal preferences and experiences, the authors write.

Arnaud Merglen, M.D., of Geneva University, Switzerland, and colleagues used data from the Geneva Cancer Registry to assess all 844 patients diagnosed with localized (not yet spread) prostate cancer in Geneva between 1989 and 1998. Of those men, 158 received prostatectomy, or surgery to remove all or part of the prostate; 205 had radiation treatment (radiotherapy); 378 chose watchful waiting, which entails active follow-up and treatment if the disease progresses; 72 underwent hormone therapy; and 31 had another type of therapy.

The average follow-up was 6.7 years (range zero to 15.8 years), and 47 patients (5.6 percent) left Geneva and the study before the study concluded.

At 10 years, patients treated with radiotherapy or watchful waiting had a significantly increased risk of death from prostate cancer compared with patients who underwent prostatectomy, the authors write. Ten-year survival rates from prostate cancer were 83 percent for prostatectomy, 75 percent for radiotherapy, 72 percent for watchful waiting, 41 percent for hormone therapy and 71 percent for other treatment. The increased mortality associated with radiotherapy and watchful waiting was primarily observed in patients younger than 70 years and in patients with poorly differentiated tumors, or tumors that have certain cellular characteristics and are more likely to spread aggressively.

Until clinical trials provide conclusive evidence, physicians and patients should be informed of these results and their limitations, the authors conclude. '/>"/>

Contact: Christine Bouchardy
christine.bouchardymagnin@imsp.unige.ch
JAMA and Archives Journals
Source:Eurekalert

Related medicine news :

1. Swiss Researchers Isolate Hair-Raising Stem Cells
2. Euthanasia To Be Permitted In Swiss Hospital
3. Swiss Group Appeals Invocation of Euthanasia Option For The Severely Depressed
4. Rural Canadians travel far for specialists: study
5. A new study surpasses Gene Therapy Hurdle
6. Tomato Sauce reduces Cancer Risk- Study
7. A question on study of Adult Stem Cell
8. Study on obesity and heart failure
9. National Lung Study in the process
10. Marijuana gateway theory strengthened by study of twins
11. Old theory of adaptation confirmed by new study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2017)... ... 23, 2017 , ... Altura Communication Solutions, a nationwide provider ... certification and SMB specialization. Altura is now qualified to sell, install and ... Select Certification, Altura fulfilled the training and exam requirements for the Cisco Small ...
(Date:4/22/2017)... (PRWEB) , ... April 22, 2017 , ... ... to his role as Vice President of Sales and Business Development at OAKWORKS, ... GPO/IDN business partner engagements, business development, and strategic planning for the company. ...
(Date:4/21/2017)... ... ... staff at Palm Beach Face is proud to announce that their practice founder, Michael ... take place on April 23rd, the London Marathon has a long tradition of raising funds ... team EMPOWER, raising money for the international charity, Smile Train. , Started in ...
(Date:4/21/2017)... ... ... Brady (NYSE:BRC), a global leader in industrial and safety printing systems ... label materials received certification for the BS5609 British Marine Standard. This internationally recognized standard ... use on chemical drums shipped by sea. , “Achieving BS5609 certification for ...
(Date:4/21/2017)... , ... April 21, 2017 , ... The Patient Advocacy ... Health System, with the 2017 Ruth Ravich Patient Advocacy Award in recognition ... advocates. DeVaro was honored with the award at The Beryl Institute’s annual Patient ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... Research and Markets has announced the ... Market Analysis By Service (Manufacturing, Research), By Country, (Brazil, Mexico, ... report to their offering. ... The Latin American pharmaceutical contract manufacturing services market ... Low drug registration cost in Latin American countries and ...
(Date:4/19/2017)... 2017 The Mobile X-Ray product segment is the ... during the forecast period Mobile X-Ray segment is ... mobile X-Ray devices market, which is estimated to be valued ... a CAGR of 7% over the forecast period. Mobile X-Ray ... than US$ 100 Mn in 2017 over 2016. The segment,s ...
(Date:4/19/2017)... NEW YORK , April 19, 2017 /PRNewswire/ ... This report on the prostate cancer ... of the global market. Increasing prevalence of prostate ... as innovation in the development of new drugs ... hormone-refractory prostate cancer drug due to lesser side ...
Breaking Medicine Technology: